674 related articles for article (PubMed ID: 28703220)
21. Tumor-Induced Osteomalacia and the Importance of Plasma Fibroblast Growth Factor 23 as an Indicator: Diagnostic Delay Leads to a Suicide Attempt.
Seemann L; Padala SA; Mohammed A; Belayneh N
J Investig Med High Impact Case Rep; 2019; 7():2324709619895162. PubMed ID: 31850815
[TBL] [Abstract][Full Text] [Related]
22. Tumor-induced osteomalacia in association with PTEN-negative Cowden syndrome.
Berglund JA; Gafni RI; Wodajo F; Cowen EW; El-Maouche D; Chang R; Chen CC; Guthrie LC; Molinolo AA; Collins MT
Osteoporos Int; 2018 Apr; 29(4):993-997. PubMed ID: 29380000
[TBL] [Abstract][Full Text] [Related]
23. Hypophosphatemia and FGF23 tumor-induced osteomalacia in two cases of metastatic breast cancer.
Abramson M; Glezerman IG; Srinivasan M; Ross R; Flombaum C; Gutgarts V
Clin Nephrol; 2021 Feb; 95(2):104-111. PubMed ID: 33191899
[TBL] [Abstract][Full Text] [Related]
24. Challenging case of tumour-induced osteomalacia.
Kumar P; Jadhav DV; Ravat SH; Jain N
BMJ Case Rep; 2022 May; 15(5):. PubMed ID: 35589273
[TBL] [Abstract][Full Text] [Related]
25. Tumor-induced osteomalacia.
Jan de Beur SM
JAMA; 2005 Sep; 294(10):1260-7. PubMed ID: 16160135
[TBL] [Abstract][Full Text] [Related]
26. [Osteomalacia due to phosphate deficiency caused by a tumor. Focus on FGF23 in physiology and clinic].
Westerberg PA; Linde T; Ljunggren O
Lakartidningen; 2012 Aug 8-21; 109(32-33):1414-6. PubMed ID: 22953430
[No Abstract] [Full Text] [Related]
27. Tumor-induced osteomalacia: An overview.
Jadhav SS; Shah R; Patil V
Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101834. PubMed ID: 37935612
[TBL] [Abstract][Full Text] [Related]
28. Phosphaturic mesenchymal tumors: what an endocrinologist should know.
Boland JM; Tebben PJ; Folpe AL
J Endocrinol Invest; 2018 Oct; 41(10):1173-1184. PubMed ID: 29446010
[TBL] [Abstract][Full Text] [Related]
29. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia.
Imel EA; Peacock M; Pitukcheewanont P; Heller HJ; Ward LM; Shulman D; Kassem M; Rackoff P; Zimering M; Dalkin A; Drobny E; Colussi G; Shaker JL; Hoogendoorn EH; Hui SL; Econs MJ
J Clin Endocrinol Metab; 2006 Jun; 91(6):2055-61. PubMed ID: 16551733
[TBL] [Abstract][Full Text] [Related]
30. Hypophosphataemia-inducing mesenchymal tumour in the foot.
Bauer C; Brücker R; Bützberger S; Schmid C
BMJ Case Rep; 2010 Oct; 2010():. PubMed ID: 22778109
[TBL] [Abstract][Full Text] [Related]
31. Cinacalcet in the management of tumor-induced osteomalacia.
Geller JL; Khosravi A; Kelly MH; Riminucci M; Adams JS; Collins MT
J Bone Miner Res; 2007 Jun; 22(6):931-7. PubMed ID: 17352646
[TBL] [Abstract][Full Text] [Related]
32. Oncogenic osteomalacia: two case reports with surprisingly different outcomes.
Seijas R; Ares O; Sierra J; Pérez-Dominguez M
Arch Orthop Trauma Surg; 2009 Apr; 129(4):533-9. PubMed ID: 19125258
[TBL] [Abstract][Full Text] [Related]
33. Tumor induced osteomalacia.
Filipová L; Lazúrová I
Vnitr Lek; 2021; 67(E-8):19-22. PubMed ID: 35459330
[TBL] [Abstract][Full Text] [Related]
34. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
35. The diagnostic dilemma of tumor induced osteomalacia: a retrospective analysis of 144 cases.
Feng J; Jiang Y; Wang O; Li M; Xing X; Huo L; Li F; Yu W; Zhong DR; Jin J; Liu Y; Qi F; Lv W; Zhou L; Meng XW; Xia WB
Endocr J; 2017 Jul; 64(7):675-683. PubMed ID: 28450684
[TBL] [Abstract][Full Text] [Related]
36. Phosphaturic mesenchymal tumor without osteomalacia: additional confirmation of the "nonphosphaturic" variant, with emphasis on the roles of FGF23 chromogenic in situ hybridization and FN1-FGFR1 fluorescence in situ hybridization.
Sent-Doux KN; Mackinnon C; Lee JC; Folpe AL; Habeeb O
Hum Pathol; 2018 Oct; 80():94-98. PubMed ID: 29514106
[TBL] [Abstract][Full Text] [Related]
37. Treatment and outcomes of tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors: retrospective review of 12 patients.
Zuo QY; Wang H; Li W; Niu XH; Huang YH; Chen J; You YH; Liu BY; Cui AM; Deng W
BMC Musculoskelet Disord; 2017 Sep; 18(1):403. PubMed ID: 28934935
[TBL] [Abstract][Full Text] [Related]
38. Favorable effects of burosumab on tumor-induced osteomalacia caused by an undetectable tumor: A case report.
Oe Y; Kameda H; Nomoto H; Sakamoto K; Soyama T; Cho KY; Nakamura A; Iwasaki K; Abo D; Kudo K; Miyoshi H; Atsumi T
Medicine (Baltimore); 2021 Nov; 100(46):e27895. PubMed ID: 34797338
[TBL] [Abstract][Full Text] [Related]
39. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia.
Shimada T; Mizutani S; Muto T; Yoneya T; Hino R; Takeda S; Takeuchi Y; Fujita T; Fukumoto S; Yamashita T
Proc Natl Acad Sci U S A; 2001 May; 98(11):6500-5. PubMed ID: 11344269
[TBL] [Abstract][Full Text] [Related]
40. Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis.
Larsson T; Marsell R; Schipani E; Ohlsson C; Ljunggren O; Tenenhouse HS; Jüppner H; Jonsson KB
Endocrinology; 2004 Jul; 145(7):3087-94. PubMed ID: 14988389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
